• FDA Approves Victoza for Type 2 Diabetes in Children and Adolescents americanpharmaceuticalreview
    June 21, 2019
    Novo Nordisk announced the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Victoza® (liraglutide) injection to lower blood sugar along with diet and exercise in children and adolescents aged 10-17 years with type 2 diabetes
PharmaSources Customer Service